跳至主要内容
临床试验/NCT01933321
NCT01933321已完成2 期

Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)

Hospital Universitario Dr. Jose E. Gonzalez2 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2012年9月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
14
试验地点
2
主要终点
Evaluation of autologous intrathecal administration of hematopoietic stem cells in patients with ALS.

研究概览

简要总结

Autologous cell therapy in patients with ALS can stimulate neuroplasticity, modifying the neurodegenerative process and stops the clinical progression of disease.

详细描述

There is no more extensive information

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with a confirmed diagnosis of ALS according to El Escorial criteria. Diagnosis-time less than four years.
  • Over 18 years old. Forced vital capacity ≥ 40%.
  • One year of evolution.
  • Adequate nutritional state

排除标准

  • Severe bulbar ALS involucre.
  • Inadequate nutritional status.
  • Spondylotic myelopathy, or abnormalities in imaging study.
  • Having concomitant neurological or psychiatric disease.
  • Systemic disease with poor-control.
  • History of treatment with steroids or immunoglobulins in the last year.
  • Participate in the past three months in a Clinical Trial.
  • History of malignancy or cancer today.
  • Intracranial hypertension.
  • Clinical suggestive data of infection in the site of lumbar puncture.
  • Tracheostomy.
  • Use of mechanical ventilation. Forced vital capacity less than 40%. HIV-seropositive or presence of antibodies against hepatitis B or C in the serological studies.

结局指标

主要结局

Evaluation of autologous intrathecal administration of hematopoietic stem cells in patients with ALS.

时间窗: up to 12 months

次要结局

  • To evaluate the safety of intrathecal administration of hematopoietic stem cells in patients with ALS.(During the procedure and at 1st, 2nd, 3rd, 6th and 12 th month after the procedure)

研究者

发起方
Hospital Universitario Dr. Jose E. Gonzalez
申办方类型
Other
责任方
Principal Investigator
主要研究者

David Gomez Almaguer

Chair of Hematology

Hospital Universitario Dr. Jose E. Gonzalez

研究点 (2)

Loading locations...

相似试验